close

Children’s lives at risk from US funding cuts to vaccine alliance: CEO

By AFP
April 25, 2026
This photograph shows a board bearing the logo of Gavi, the vaccine alliance at their headquarters in Geneva, on April 11, 2025. — AFP
This photograph shows a board bearing the logo of Gavi, the vaccine alliance at their headquarters in Geneva, on April 11, 2025. — AFP

NAIROBI: The head of a global vaccine organisation told AFP on Friday that aid cuts by the United States and other donors have forced it to slash its malaria programme in Africa, threatening tens of thousands of children´s lives.

Gavi, the Vaccine Alliance, brings together government and private donors to help developing countries acquire jabs for key diseases at affordable prices.

Last year, the United States pulled support worth $1.58 billion, with its vaccine-sceptic health secretary Robert F. Kennedy Jr claiming without evidence that there were safety concerns.

“Our malaria programme has taken the heaviest cuts,” Gavi CEO Sania Nishtar told AFP in an interview from Rwanda.

Gavi has been supporting the rollout of the malaria vaccine, approved in 2021, in 25 countries across Africa, where the disease claims some 600,000 lives a year, mostly children.

The goal of reaching 85 per cent coverage in the targeted countries by 2030 has been reduced to 70 percent, she said.

Gavi had projected the rollout would prevent 180,000 deaths, and while final spending choices still rest with African governments, the impact of the cuts “will likely be tens of thousands of children´s lives lost”, said Nishtar.

“This is hugely disappointing,” she added.

“If you´ve ever seen a child with malaria convulsions in a hospital, you know what this means. It´s a horrible sight.”

Nishtar also told AFP of the challenges in its effort to develop vaccine manufacturing in Africa -- an issue brought into stark relief during the Covid pandemic when developed countries hoarded jabs, leaving Africans last in line.

Gavi announced a $1 billion subsidy programme in 2024 to help potential African vaccine-makers get up and running.

But 18 months later, “none of the manufacturers have been able to redeem a subsidy as of now”, said Nishtar.

Firms in South Africa, Senegal, Morocco and Ghana are among those in the hunt but Nishtar said it was clear they needed more upfront financing and support to get labs and production lines off the ground, and she would be proposing that to Gavi´s board in July.

“We are bending backwards to help but we don´t have a magic wand,” she said, calling on African governments to help with tax breaks and investments of their own.

Gavi had aimed to collect $11.9 billion for its 2026-2030 strategy but is still short by $1.9 billion, mostly due to the US withdrawal but also caused by reductions from other Western donors.